MedinCell S.A.
ISIN: FR0004065605 | Ticker: MEDCL | LEI: 969500R79U6PXCL2FF46
Country: France
MedinCell® is a pharmaceutical company at premarketing stage that develops innovative long-acting injectable medicines in many therapeutic areas. Products of our portfolio are based on our BEPO® technology and aim to ensure patient compliance, improve the effectiveness and accessibility of treatments, and reduce their environmental footprint. We collaborate with tier one pharmaceuticals companies and foundations to improve Global Health through new therapeutic options.
Year founded2003
Served areaWorldwide
Headcount147
Headquarters3 Rue des Frères Lumière, 34380 Jacou – France
| Line item in (eur) | 01.04.2020 | 01.04.2021 | 01.04.2022 |
|---|---|---|---|
| Assets | N/A | 63,606,000.00 | 44,303,000.00 |
| Noncurrent Assets | N/A | 7,281,000.00 | 10,229,000.00 |
| Property Plant And Equipment | N/A | 2,676,000.00 | 3,433,000.00 |
| Intangible Assets Other Than Goodwill | N/A | 1,486,000.00 | 1,666,000.00 |
| Investment Accounted For Using Equity Method | N/A | 12,000.00 | 14,000.00 |
| Deferred Tax Assets | N/A | 0.00 | 0.00 |
| Other Noncurrent Financial Assets | N/A | 1,929,000.00 | 1,519,000.00 |
| Current Assets | N/A | 56,325,000.00 | 34,074,000.00 |
| Inventories | N/A | 0.00 | 0.00 |
| Trade And Other Current Receivables | N/A | 883,000.00 | 799,000.00 |
| Current Tax Assets Current | N/A | 0.00 | 0.00 |
| Other Current Financial Assets | N/A | 3,503,000.00 | 2,566,000.00 |
| Other Current Nonfinancial Assets | N/A | 4,844,000.00 | 6,092,000.00 |
| Cash and cash equivalents | 12,377,000.00 | 47,095,000.00 | 24,617,000.00 |
| Equity And Liabilities | N/A | 63,606,000.00 | 44,303,000.00 |
| Equity | -15,760,000.00 | 9,127,000.00 | -13,371,000.00 |
| Issued Capital | N/A | 247,000.00 | 251,000.00 |
| Share Premium | N/A | 75,147,000.00 | 6,913,000.00 |
| Reserve Of Sharebased Payments | 0.00 | 0.00 | N/A |
| Equity Attributable To Owners Of Parent | N/A | 9,127,000.00 | -13,371,000.00 |
| Noncontrolling Interests | N/A | 0.00 | 0.00 |
| Noncurrent Liabilities | N/A | 40,878,000.00 | 19,433,000.00 |
| Noncurrent Provisions For Employee Benefits | N/A | 240,000.00 | 265,000.00 |
| Other Longterm Provisions | N/A | 20,000.00 | 20,000.00 |
| Other Noncurrent Financial Liabilities | N/A | 39,071,000.00 | 16,249,000.00 |
| Other Noncurrent Nonfinancial Liabilities | N/A | 840,000.00 | 0.00 |
| Current Liabilities | N/A | 13,600,000.00 | 38,241,000.00 |
| Current Provisions | N/A | 99,000.00 | 102,000.00 |
| Trade And Other Current Payables | N/A | 2,956,000.00 | 2,982,000.00 |
| Current Tax Liabilities Current | N/A | 0.00 | 0.00 |
| Other Current Nonfinancial Liabilities | N/A | 6,976,000.00 | 6,812,000.00 |
| Current Borrowings And Current Portion Of Noncurrent Borrowings | N/A | 3,179,000.00 | 27,764,000.00 |
| Line item in (eur) | 01.04.2020/ 01.04.2021 |
01.04.2021/ 01.04.2022 |
|---|---|---|
| Revenue | 11,775,000.00 | 8,338,000.00 |
| Interest Income On Cash And Cash Equivalents | 40,000.00 | 90,000.00 |
| Revenue From Contracts With Customers | 8,186,000.00 | 4,090,000.00 |
| Other Income | 3,589,000.00 | 4,247,000.00 |
| Profit Loss From Operating Activities | -15,576,000.00 | -23,814,000.00 |
| Finance Income | -3,410,000.00 | -992,000.00 |
| Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method | 0.00 | 0.00 |
| Profit Loss Before Tax | -18,986,000.00 | -24,806,000.00 |
| Income Tax Expense Continuing Operations | 0.00 | 0.00 |
| Profit (loss) | -18,986,000.00 | -24,806,000.00 |
| Profit Loss Attributable To Owners Of Parent | -18,986,000.00 | -24,806,000.00 |
| Profit Loss Attributable To Noncontrolling Interests | 0.00 | 0.00 |
| Line item in (eur) | 01.04.2020 | 01.04.2021 | 01.04.2022 |
|---|---|---|---|
| Profit (loss) | N/A | -18,986,000.00 | -24,806,000.00 |
| Adjustments For Reconcile Profit Loss | N/A | 6,227,000.00 | 5,811,000.00 |
| Adjustments For Income Tax Expense | N/A | 0.00 | 0.00 |
| Adjustments For Decrease Increase In Inventories | N/A | 0.00 | 0.00 |
| Adjustments For Decrease Increase In Other Operating Receivables | N/A | -955,000.00 | -1,472,000.00 |
| Adjustments For Increase Decrease In Trade Account Payable | N/A | -180,000.00 | 26,000.00 |
| Adjustments For Increase Decrease In Other Operating Payables | N/A | 2,023,000.00 | -1,005,000.00 |
| Adjustments For Depreciation And Amortisation Expense | N/A | 1,339,000.00 | 1,516,000.00 |
| Adjustments For Provisions | N/A | 86,000.00 | 86,000.00 |
| Adjustments For Sharebased Payments | N/A | 1,563,000.00 | 2,394,000.00 |
| Other Adjustments For Noncash Items | N/A | -303,000.00 | 20,000.00 |
| Adjustments For Losses Gains On Disposal Of Noncurrent Assets | N/A | 0.00 | -3,000.00 |
| Adjustments For Reconcile Profit Loss | N/A | 6,227,000.00 | 5,811,000.00 |
| Income Taxes Paid Refund Classified As Operating Activities | N/A | 0.00 | 0.00 |
| Cash Flows From Used In Operating Activities | N/A | -12,134,000.00 | -21,362,000.00 |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | N/A | 645,000.00 | 1,623,000.00 |
| Purchase Of Intangible Assets Classified As Investing Activities | N/A | 174,000.00 | 351,000.00 |
| Interest Received Classified As Investing Activities | N/A | 41,000.00 | 95,000.00 |
| Other Inflows Outflows Of Cash Classified As Investing Activities | N/A | -284,000.00 | 197,000.00 |
| Cash Flows From Used In Investing Activities | N/A | -1,062,000.00 | -316,000.00 |
| Proceeds From Issuing Shares | N/A | 42,004,000.00 | 48,000.00 |
| Payments To Acquire Or Redeem Entitys Shares | N/A | -281,000.00 | 192,000.00 |
| Proceeds From Borrowings Classified As Financing Activities | N/A | 18,706,000.00 | 3,308,000.00 |
| Repayments Of Borrowings Classified As Financing Activities | N/A | 9,265,000.00 | 2,307,000.00 |
| Payments Of Lease Liabilities Classified As Financing Activities | N/A | 306,000.00 | 531,000.00 |
| Interest Paid Classified As Financing Activities | N/A | 3,504,000.00 | 1,126,000.00 |
| Cash Flows From Used In Financing Activities | N/A | 47,917,000.00 | -800,000.00 |
| Increase (decrease) in cash and cash equivalents after effect of exchange rate changes | N/A | 34,718,000.00 | -22,478,000.00 |
| Cash and cash equivalents | 12,377,000.00 | 47,095,000.00 | 24,617,000.00 |
Please note that some sums might not add up.
| Date | Trading entity / Person | Association | Trade type | Volume |
|---|---|---|---|---|
| 02.05.23 | None | Other | Sell | EUR 600,006.00 |
FR0004065605
LEI969500R79U6PXCL2FF46
SectorPharmaceuticals, Biotechnology & Life Sciences
IndustryKeep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.